Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Stenke

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Leukemia|May 3, 2017
No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in SwedenN Gunnarsson, M Höglund, L Stenke, et al.
Leukemia|June 8, 2011
Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivationA Kreutzman, K Ladell, C Koechel, et al.
Lakartidningen|September 17, 1980
[Medical prepardness at marathon races. Experiences from the Stockholm marathon]K Boman, L Ehn, C E Leijonmarck, et al.
Radiation Protection Dosimetry|August 14, 2016
Using the Grade Approach to Support the Development of Recommendations for Public Health Interventions in Radiation EmergenciesZ Carr, M Clarke, E A Akl, et al.
Leukemia|April 16, 2016
Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemiaN Gunnarsson, M Höglund, L Stenke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemiaU Tidefelt, J Liliemark, A Gruber, et al.
European Journal of Haematology|September 13, 2002
Long-term follow-up of patients >or=60 yr old with acute myeloid leukaemia treated with intensive chemotherapyG Oberg, A Killander, M Björeman, et al.
Oncogene|April 4, 2017
Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cellsH S Madapura, N Nagy, D Ujvari, et al.
Leukemia|January 19, 2013
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patientsS Mustjoki, J Richter, G Barbany, et al.
Leukemia|March 20, 2009
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapyS Mustjoki, M Ekblom, T P Arstila, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Leukemia|May 3, 2017
No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in SwedenN Gunnarsson, M Höglund, L Stenke, et al.
Leukemia|June 8, 2011
Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivationA Kreutzman, K Ladell, C Koechel, et al.
Lakartidningen|September 17, 1980
[Medical prepardness at marathon races. Experiences from the Stockholm marathon]K Boman, L Ehn, C E Leijonmarck, et al.
Radiation Protection Dosimetry|August 14, 2016
Using the Grade Approach to Support the Development of Recommendations for Public Health Interventions in Radiation EmergenciesZ Carr, M Clarke, E A Akl, et al.
Leukemia|April 16, 2016
Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemiaN Gunnarsson, M Höglund, L Stenke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemiaU Tidefelt, J Liliemark, A Gruber, et al.
European Journal of Haematology|September 13, 2002
Long-term follow-up of patients >or=60 yr old with acute myeloid leukaemia treated with intensive chemotherapyG Oberg, A Killander, M Björeman, et al.
Oncogene|April 4, 2017
Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cellsH S Madapura, N Nagy, D Ujvari, et al.
Leukemia|January 19, 2013
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patientsS Mustjoki, J Richter, G Barbany, et al.
Leukemia|March 20, 2009
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapyS Mustjoki, M Ekblom, T P Arstila, et al.
Pageof 6